Thomas Unger, PhD is a co-founder of Naia Limited and currently serves as chief strategy officer. Previously, he was at Pfizer Inc. where he held a number of senior roles within the Development Operations and Worldwide Regulatory Strategy organizations.

His previous roles included head of strategy for Pfizer’s Biotherapeutics and Bioinnovation Center (BBC). He joined Pfizer as Development Strategy Lead for the Strategic Management Group within Pfizer Global Research and Development (PGRD), where he was a member of the Development Leadership Team and responsible for leading strategic and operational initiatives within the R&D organization.

While at Pfizer, Dr. Unger was responsible for initiating several innovative efforts that spanned business strategy, operational change and clinical development programs. He was also responsible for initiating a number of collaborative innovation initiatives, including co-founding the Massachusetts Institute of Technology’s NEW Drug Development ParaDIGmS (NEWDIGS) program, for which he serves as a member of the Executive Committee and senior advisor.

Before joining Pfizer, Dr. Unger held a number of senior strategic advisory positions including at the investment banking firm Aperion Partners, LLC and MTM Advisors, LLC, and the management consulting firms Wood Mackenzie Limited and PA Consulting Group.

He started his industry career as co-founder of a number of early-stage biotechnology companies, including BioLogic Technologies and Miragen Incorporated. He currently serves on the advisory boards of a number of companies, including bigfinite and Bullet Biotechnology and foundations.

Dr. Unger earned his PhD in Biological Sciences from the California College of Medicine, University of California, Irvine and his MBA from the Marshall School of Business, University of Southern California.